PLAB Practice Exam 2026 – Complete Test Prep

Beta-blockers are used cautiously in the context of benign prostatic hyperplasia (BPH) primarily because they may exacerbate heart failure. Many patients with BPH are older and may have comorbidities, including cardiovascular conditions. Beta-blockers can potentially decrease cardiac output by reducing heart rate and contractility, which may lead to worsened heart failure symptoms in susceptible individuals.

In patients already compromised by heart failure, the additional strain of managing BPH could lead to a negative clinical outcome, necessitating careful monitoring or alternative treatment strategies. While the other options present relevant considerations, they do not capture the significant concern regarding the impact of beta-blockers on heart function, making this reason particularly critical in the management of BPH in patients with concurrent cardiac issues.